Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Equine herpes myeloencephalopathy.

C W Kohn, W R Fenner

    The Veterinary Clinics of North America. Equine Practice
    |August 1, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Equine herpesvirus-1 (EHV-1) causes neurologic disease through central nervous system infarction. While no vaccine protects against EHV-1

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Interobserver Variation in the Diagnosis of Neurologic Abnormalities in the Horse.

    Journal of veterinary internal medicine·2017
    Same author

    Epilepsy in horses: aetiological classification and predictive factors.

    Equine veterinary journal·2011
    Same author

    Cloning, comparative sequence analysis and mRNA expression of calcium-transporting genes in horses.

    General and comparative endocrinology·2010
    Same author

    Rapid calcitonin response to experimental hypercalcemia in healthy horses.

    Domestic animal endocrinology·2009
    Same author

    Blood arginine vasopressin, adrenocorticotropin hormone, and cortisol concentrations at admission in septic and critically ill foals and their association with survival.

    Journal of veterinary internal medicine·2008
    Same author

    Effects of dietary glycaemic response after exercise on blood concentrations of substrates used indirectly for muscle glycogenesis.

    Equine veterinary journal. Supplement·2007
    Same journal

    Pharmaceutical and Nutraceutical Therapies for Liver Disease.

    The Veterinary clinics of North America. Equine practice·2026
    Same journal

    Clinical Signs of Liver Disease in Horses.

    The Veterinary clinics of North America. Equine practice·2026
    Same journal

    Syndrome of High Gamma-Glutamyl Transferase in Racehorses.

    The Veterinary clinics of North America. Equine practice·2026
    Same journal

    Equine Hepatology in Practice: Insights, Challenges, and Progress.

    The Veterinary clinics of North America. Equine practice·2026
    Same journal

    Pathophysiology and Treatment of Hepatic Encephalopathy.

    The Veterinary clinics of North America. Equine practice·2026
    Same journal

    Viral Hepatitis.

    The Veterinary clinics of North America. Equine practice·2026
    See all related articles

    Area of Science:

    • Veterinary Neurology
    • Equine Infectious Diseases
    • Virology

    Background:

    • Equine herpesvirus-1 (EHV-1), subtype 1, is the causative agent of a serious neurologic disease in horses.
    • The neurologic form is characterized by central nervous system infarction, stemming from vasculitis initiated in small blood vessel endothelial cells.
    • The exact mechanism, whether direct viral effect or immune response, causing vasculitis remains undetermined.

    Purpose of the Study:

    • To elucidate the pathogenesis of EHV-1 neurologic disease.
    • To discuss diagnostic challenges and prognosis.
    • To review current therapeutic and preventative strategies, including vaccination.

    Main Methods:

    • Review of existing literature on EHV-1 neurologic disease.

    Related Experiment Videos

  • Analysis of clinical signs, diagnostic limitations, and prognostic factors.
  • Evaluation of therapeutic interventions and vaccine efficacy.

    • Main Results:

    • Clinical signs are acute, nonprogressive, with potential for improvement.
    • Diagnosis is often tentative due to lack of a single confirmatory test.
    • Prognosis is generally fair, though recovery can be slow and incomplete.

    Conclusions:

    • Supportive care and corticosteroids may aid recovery; no specific antiviral or anti-vasculitis therapy exists.
    • Current vaccines do not guarantee protection against the neurologic form but are recommended for reducing other EHV-1 manifestations.
    • Regular vaccination may indirectly lower the incidence of neurologic EHV-1 by reducing overall farm infection rates.